ProBioGen's GlymaxX® Technology reaches Phase III Clinical Development
Berlin, December 17, 2021: ProBioGen AG, a leading technology developer and CDMO for cell line development through GMP manufacturing announces an important clinical milestone for..
ProBioGen's GlymaxX® Technology made it again into Clinical Phase I
Berlin, November 17, 2021: ProBioGen, a premier CDMO for cell line development through GMP manufacturing which has also developed innovative technologies, announced that another..
PEGS Europe 2021: ProBioGen's Presentation shows how the DirectedLuck™ Transposase System streamlines Cell Line Development
Barcelona, Spain, November 3, 2021: ProBioGen is delighted to announce that today, its Chief Scientific Officer Dr. Volker Sandig has presented at 13th annual PEGS Europe Protein..
ProBioGen’s DirectedLuck™ Transposase Licensed by TOP15 Global BioPharma Company
Berlin, Germany, September 28, 2021: ProBioGen today announced the closing of a DirectedLuck Transposase Technology research license agreement with another global biopharma..
Nobelpharma signs a License Agreement for ProBioGen’s Vaccine Manufacturing Platform AGE1.CR.pIX®
Berlin, Germany, August 12, 2021: ProBioGen is pleased to announce that Nobelpharma has signed a license agreement for the use of the AGE1.CR.pIX vaccine production platform to..
ValenzaBio partners with ProBioGen to maximize cell line productivity and licenses GlymaxX®
Berlin, Germany and Bethesda, MD, USA, July 27, 2021: ProBioGen and ValenzaBio today jointly announced the initiation of a cell line development project involving the application..
Heat Biologics enters into Research License Agreement for ProBioGen's Transposase System and Suspension HEK293 Cell Line
Berlin, Germany, July 13, 2021: ProBioGen announced today that they have entered into a research license agreement with Heat Biologics for both ProBioGen's Transposase System..
Dr. Simon Bulling Joins ProBioGen as Chief Operating Officer to Drive Next Phase of Operational Growth
Apr 21, 2026
ProBioGen Introduces CMC Navigator™ to Help Biopharma Teams Select the Best CMC Path Forward
Feb 17, 2026
ProBioGen and Zag Bio™ Forge Strategic CMC Partnership to Advance Fc-Fusion Autoimmune Therapy
Jan 6, 2026
ProBioGen and Spica Therapeutics Announce Collaboration on GlymaxX-Enhanced CLD for Spica’s Clinical Development Candidate ST101
Dec 9, 2025
IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa
Oct 10, 2025
%20kooperieren%20im%20Berlin%20Center%20for%20Gene%20und%20Cell%20Therapies%20(BC%20GCT)-2.webp)
ProBioGen to Lead GMP Manufacturing Operations at Berlin Center for Gene and Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen und das Berlin Institute of Health in der Charité (BIH) kooperieren im Berlin Center for Gene und Cell Therapies (BC GCT)
Sep 16, 2025
ProBioGen Enters Agreement with Polpharma Biologics to Provide High-Performance Cell Line Development Services
May 7, 2025
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
